Evidence map›Paper›PMID 41256083›Full record

ArticleJournal of clinical practice and research2025

Experience of Using a Bruton Tyrosine Kinase (BTK) Inhibitor in Primary Testicular Diffuse Large B-Cell Lymphoma (DLBCL) with Isolated Central Nervous System (CNS) Metastasis.

Santhosh Meedimale, Soumya Surath Panda, Adya Kinkar Panda, Debahuti Mohapatra, Rajesh Kumar Bhola, Lalatendu Moharana, Swati Sucharita Mohanty, Lipsita Samantaray

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Santhosh MeedimaleDepartment of Medical Oncology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.
Soumya Surath PandaDepartment of Medical Oncology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.
Adya Kinkar PandaDepartment of Radiology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.
Debahuti MohapatraDepartment of Pathology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences, Sum Hospital, Bhubaneswar, India.
Rajesh Kumar BholaDepartment of Pathology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences, Sum Hospital, Bhubaneswar, India.
Lalatendu MoharanaDepartment of Medical Oncology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.
Swati Sucharita MohantyDepartment of Medical Oncology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.
Lipsita SamantarayDepartment of Medical Oncology, Siksha 'O' Anusandhan Deemed to be University, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary testicular lymphoma (PTL) is a rare subtype of non-Hodgkin's lymphoma (NHL), most commonly presenting as diffuse large B-cell lymphoma (DLBCL). It primarily affects older men and has a tendency to relapse in the central nervous system (CNS), contralateral testis, and lungs. Although rituximab has improved survival outcomes, its limited CNS penetration is a clinical challenge. Case Report: We report the case of a 39-year-old man diagnosed with primary testicular DLBCL (PT-DLBCL) (triple expresser). He received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (oncovin), and prednisone) combined with high-dose methotrexate (HD-MTX) and contralateral testicular radiation. After 33 months of disease-free survival, he experienced a CNS relapse. He was subsequently treated with the MAR (methotrexate, cytarabine, and rituximab) regimen, consisting of HD-MTX, cytarabine (Ara-C), and rituximab. Following whole-brain radiotherapy and rituximab maintenance therapy, he achieved complete response and was transitioned to maintenance therapy with acalabrutinib. Conclusion: This case highlights the successful use of the MAR regimen and acalabrutinib maintenance in a patient with CNS-relapse PT-DLBCL. Further studies are needed to develop standardized treatment protocols for such high-risk cases.

Indexed as

acalabrutinibBTK inhibitorCNS prophylaxisDLBCLextranodal sites

Identifiers

PMID41256083
PMCPMC12478694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.